Tumor subtype did not predict who got better after pituitary surgery
Original title: Association between pathological subtypes of PitNETs and postoperative biochemical remission in acromegaly.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This study only watched patients who had surgery, and tested no new treatment.
The short version
In this study, the tumor's cell type did not change who went into remission after surgery.
What was studied. Doctors studied people with acromegaly who had pituitary tumor surgery. The surgeries took place between January 2015 and October 2025. Each tumor was sorted into groups by the proteins its cells made.
What they found. Just over half of the patients went into remission, 51.0%. Most tumors were in the larger size group, 93.4%. Tumors with only the PIT-1 protein made up 62.3%, and tumors with only growth hormone made up 19.2%. The groups had about the same chance of remission.
What this means, and what it doesn't
What it could mean: For now, the tumor's subtype alone may not tell you how well surgery will work. Doctors still need better ways to judge the odds before surgery.
What it doesn't mean: This does not mean tumor type never matters. The study watched patients over time. It did not test a new drug or a new kind of surgery. Nothing here changes care you can get today, and it is not a promise of a cure.
Source: PubMed, October 31, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.